8 results
ARS
2024 FY
CCCC
C4 Therapeutics Inc
30 Apr 24
Annual report to shareholders
8:52am
is particularly common in NSCLC patients of Asian heritage. In China, where approximately 693,000 patients are diagnosed Table of Contents 12
with NSCLC
ARS
2023 FY
CCCC
C4 Therapeutics Inc
28 Apr 23
Annual report to shareholders
7:03am
and between 10 and 15% of these patients have mutant EGFR, or mEGFR. The EGFR mutation is particularly common in NSCLC patients of Asian heritage. In China
PRE 14A
wll17gygd txz6a437qb
18 Apr 23
Preliminary proxy
7:59am
8-K
EX-99.2
uywlay4xzh4r0wlq2
7 Jun 21
C4 Therapeutics Presents Pre-clinical Data on CFT8919, A Selective Degrader of EGFR L858R, at Keystone Symposium on Targeted Protein Degradation
7:25am
- Prev
- 1
- Next